Zacks Research Analysts Lift Earnings Estimates for Sanofi

Sanofi (NASDAQ:SNY) – Equities research analysts at Zacks Research lifted their Q1 2027 earnings per share (EPS) estimates for shares of Sanofi in a report issued on Monday, April 14th. Zacks Research analyst K. Shah now anticipates that the company will post earnings of $1.12 per share for the quarter, up from their previous estimate of $1.11. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s FY2027 earnings at $4.84 EPS.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

SNY has been the subject of several other research reports. BNP Paribas initiated coverage on Sanofi in a research report on Tuesday. They set an “outperform” rating and a $65.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target for the company. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and a consensus price target of $63.33.

Sanofi Stock Up 0.7 %

Sanofi stock opened at $50.90 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a fifty-two week low of $45.79 and a fifty-two week high of $60.12. The firm has a fifty day moving average price of $54.73 and a two-hundred day moving average price of $52.19. The firm has a market cap of $128.59 billion, a price-to-earnings ratio of 20.44, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. This is an increase from Sanofi’s previous annual dividend of $1.48. Sanofi’s payout ratio is currently 59.04%.

Hedge Funds Weigh In On Sanofi

Hedge funds have recently made changes to their positions in the business. Synergy Asset Management LLC bought a new stake in Sanofi in the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. boosted its holdings in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after purchasing an additional 242 shares during the period. Lee Danner & Bass Inc. acquired a new position in shares of Sanofi in the 4th quarter worth approximately $31,000. Finally, Sierra Ocean LLC bought a new position in shares of Sanofi during the 4th quarter worth approximately $44,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.